Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo’s omeprazole OTC?

This article was originally published in The Tan Sheet

Executive Summary

FDA issues an approvable letter to Perrigo's Israeli partner, Dexcel Pharma Technologies, for its generic Prilosec OTC (omeprazole 20 milligrams) new drug application on Dec. 18, according to the Allegan, Mich.-based firm in a same-day release. Perrigo plans on being the exclusive marketer and distributor of Dexcel's generic Prilosec OTC in the U.S. once the agency approves the application, the firm states. Currently, the company is facing pending litigation from AstraZeneca over the generic version of the over-the-counter heartburn drug. Dexcel filed the ANDA for OTC omeprazole in April 2006. Patent-holder AstraZeneca filed lawsuits in Delaware and Virginia in late May, alleging Dexcel's application infringes on three patents: two expiring in Oct. 2007 and one slated to expire in May 2019 (1"The Tan Sheet" June 12, 2006, p. 5). The litigation has initiated the patent challenge process under Hatch/Waxman and places a 30-month stay on FDA approval of the generic Prilosec OTC...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel